Michel Vounatsos

Michel Vounatsos
Nationality	French
Occupation	Business executive
Employer	Lenis Group (Chairman)
Known for	Former CEO of Biogen, oversight of Aduhelm FDA approval

Michel Vounatsos is a French pharmaceutical and biotechnology executive who served as the Chief Executive Officer of Biogen Inc., one of the world's largest biotechnology companies, from 2017 until his departure in 2022. His tenure at Biogen was defined in large part by the company's pursuit and eventual FDA approval of Aduhelm (aducanumab) in June 2021, a treatment for Alzheimer's disease that became one of the most debated drug approvals in modern pharmaceutical history. The approval generated intense scrutiny from the scientific community, healthcare policymakers, and the public over questions of clinical efficacy, the FDA's accelerated approval pathway, and the drug's initial pricing. Before ascending to the CEO role, Vounatsos had served as Biogen's Executive Vice President and Chief Commercial Officer. Following his departure from Biogen, Vounatsos has remained active in the life sciences industry, joining the boards of several companies focused on artificial intelligence in drug development and biomedical innovation. In December 2025, he was named Chairman of the Lenis Group following its acquisition by Great Point Partners.

Career

Early career and rise at Biogen

Prior to becoming CEO, Vounatsos held the position of Executive Vice President and Chief Commercial Officer at Biogen Inc., where he oversaw the company's global commercial operations. In this role, he was responsible for the commercialization strategy of Biogen's portfolio, which included treatments for multiple sclerosis, spinal muscular atrophy, and other neurological conditions. His commercial leadership positioned him as a candidate for the top executive role at the company.

Vounatsos was appointed Chief Executive Officer of Biogen, succeeding in the role and taking on responsibility for leading one of the biotechnology industry's most prominent firms. Under his leadership, Biogen maintained its focus on neuroscience as a core therapeutic area, a strategic direction that would come to define his tenure through the company's high-profile bet on an Alzheimer's disease treatment.

Aduhelm and the Alzheimer's controversy

The most consequential chapter of Vounatsos's time as CEO of Biogen centered on the development and regulatory approval of Aduhelm (aducanumab), a monoclonal antibody designed to reduce amyloid-beta plaques in the brains of patients with early-stage Alzheimer's disease. The drug's path to market was fraught with scientific debate, regulatory drama, and commercial difficulties that would ultimately reshape Vounatsos's legacy and Biogen's strategic direction.

Biogen and its Japanese partner Eisai had been developing aducanumab through a series of clinical trials. In March 2019, Biogen halted two large Phase III clinical trials — known as ENGAGE and EMERGE — after an independent data monitoring committee determined that the trials were unlikely to meet their primary endpoints. However, subsequent analysis of additional data led Biogen to announce later that year that one of the trials, EMERGE, had in fact met its primary endpoint when a larger dataset was considered, and the company moved to file for FDA approval.

The FDA's decision to approve Aduhelm on June 7, 2021, under the accelerated approval pathway was immediately controversial. On the day of the approval, Vounatsos appeared on CNBC's "Power Lunch" to discuss the milestone, framing it as a significant advance for patients suffering from Alzheimer's disease. The approval was based on the drug's ability to reduce amyloid-beta plaques, a surrogate endpoint, rather than on definitive evidence of clinical benefit in slowing cognitive decline.

The approval triggered a wave of criticism. Several members of the FDA's own advisory committee, which had voted against recommending approval, resigned in protest. Scientists and physicians questioned whether reducing amyloid plaques translated into meaningful clinical improvement for patients. The controversy also led to congressional investigations and an Office of Inspector General probe into the interactions between Biogen and the FDA during the review process.

The initial list price of Aduhelm — set at approximately $56,000 per year per patient — drew further criticism from healthcare economists, insurers, and patient advocacy groups. The Centers for Medicare & Medicaid Services (CMS) subsequently announced that it would severely restrict Medicare coverage of the drug, limiting it largely to patients enrolled in approved clinical trials. Biogen later cut the price roughly in half, but the commercial damage had been done. Uptake of Aduhelm was far below the company's projections, and the drug became a significant financial burden rather than the blockbuster revenue source that had been anticipated.

Departure from Biogen

On May 3, 2022, Biogen announced that Vounatsos would be departing as CEO once a successor was identified. The announcement came as part of a broader strategic overhaul that included the dismantling of Aduhelm's dedicated commercial team and approximately $1 billion in cost-cutting measures.

Fierce Pharma reported that Vounatsos was "ending his five-year-plus tenure" at the helm of Biogen, characterizing the leadership change as occurring "amid Aduhelm fallout." BioSpace described the move as Biogen appearing "to concede defeat over Aduhelm," noting that Vounatsos planned to remain in place until a successor was found. The leadership transition reflected a broader reckoning within the company over its Alzheimer's strategy and the commercial failure of Aduhelm. Biogen's stock price had declined substantially from its post-approval highs as the market digested the reality of limited Aduhelm uptake and the CMS coverage restrictions.

Christopher Viehbacher, a German-Canadian pharmaceutical executive who had previously served as CEO of Sanofi, was subsequently named as Vounatsos's successor, joining Biogen as President and Chief Executive Officer and member of the Board of Directors in November 2022.

Post-Biogen activities

Following his departure from Biogen, Vounatsos transitioned into advisory and board roles within the life sciences and healthcare technology sectors. In January 2024, Quris-AI, an artificial intelligence company focused on disrupting pharmaceutical drug development, announced that Vounatsos had joined its Board of Directors. The company described him as bringing significant expertise from his tenure leading a major biotechnology firm.

In February 2024, AIVITA Biomedical, Inc., a biotechnology company specializing in stem cell applications, announced Vounatsos's appointment to its Board of Directors. The company, based in Irvine, California, described the appointment as strengthening its board with pharmaceutical industry expertise.

In December 2025, Great Point Partners, a Greenwich, Connecticut-based healthcare-focused private investment firm, announced it had acquired a majority stake in the Lenis Group and named Vounatsos as Chairman of the company. The appointment represented a return to a prominent operational leadership role for Vounatsos within the healthcare services sector.

Legacy

Michel Vounatsos's tenure as CEO of Biogen is inextricably linked to the Aduhelm saga, which became a defining case study in pharmaceutical development, regulatory policy, and drug pricing in the early 2020s. The Aduhelm approval and its aftermath raised fundamental questions about the FDA's accelerated approval pathway, the role of surrogate endpoints in drug regulation, and the pricing of novel therapies for common diseases.

The commercial failure of Aduhelm — driven by CMS's coverage restrictions, limited physician adoption, and ongoing scientific skepticism about the drug's clinical benefit — led directly to the strategic restructuring at Biogen that included Vounatsos's departure and approximately $1 billion in cost reductions. The episode also influenced the broader landscape of Alzheimer's drug development. Subsequent amyloid-targeting therapies, including lecanemab (marketed as Leqembi by Eisai and Biogen), benefited from clearer clinical trial data demonstrating cognitive benefit, and their regulatory and commercial paths were shaped in part by lessons drawn from the Aduhelm experience.

Vounatsos's post-Biogen career, encompassing board roles at companies such as Quris-AI and AIVITA Biomedical and his chairmanship of Lenis Group, reflects a continued engagement with innovation in healthcare and life sciences. His experience navigating one of the pharmaceutical industry's most scrutinized drug launches has informed his perspective on the intersection of drug development, regulatory strategy, and commercial execution.

The Aduhelm controversy also had lasting implications for the relationship between the FDA and the pharmaceutical industry, contributing to increased scrutiny of the accelerated approval process and calls for reform. Congressional hearings examined the FDA's decision-making process, and the episode became a reference point in debates over how drugs should be evaluated, priced, and covered by government insurance programs.